

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com (Rs. In lakhs)


STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2015

Particulars	Standalone					
	Three months ended			Nine months ended		Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from operations						
(a) Net sales/income from operations (Net of excise duty)	230,202	212,297	207,436	658,813	599,758	801,800
(b) Other operating income	6,276	5,296	2,363	17,220	5,911	7,710
Total income from operations (net)	236,478	217,593	209,799	676,033	605,669	809,510
2 Expenses						
(a) Cost of material consumed	114,986	104,680	98,365	330,181	288,000	392,033
(b) Purchase of stock-in-trade	273	194	179	476	1,462	1,576
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7,462)	(1,612)	1,216	(14,305)	(5,527)	(15,909)
(d) Employee benefits expense	20,689	19,686	17,262	59,557	48,024	66,875
(e) Depreciation and amortisation expense	6,721	6,553	5,955	19,589	18,249	24,515
(f) Provision for decline in the value of long-term investment	-	-	-	-	-	5,400
(g) Other expenses	38,946	39,549	36,438	116,089	98,714	134,493
Total expenses	174,153	169,050	159,415	511,587	448,922	608,983
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	62,325	48,543	50,384	164,446	156,747	200,527
4 Other Income	171	299	1,171	2,945	3,605	4,232
5 Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/ loss and exceptional items (3+4)	62,496	48,842	51,555	167,391	160,352	204,759
6 Finance costs (refer note 4)	1,740	1,667	1,485	4,911	4,249	5,658
7 Foreign exchange (Gain)/Loss (refer note 4)	(551)	2,468	1,086	2,415	4,855	5,067
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	61,307	44,707	48,984	160,065	151,248	194,034
9 Exceptional item	-	-	-	-	-	-
10 Profit/(Loss) from ordinary activities before tax (8-9)	61,307	44,707	48,984	160,065	151,248	194,034
11 Tax expense/(credit)	14,736	10,698	9,557	38,883	33,315	42,400
12 Net Profit/(Loss) for the period (10-11)	46,571	34,009	39,427	121,182	117,933	151,634
13 Paid-up Equity Share Capital (Face value Re. 1 per share)	5,840	5,840	2,915	5,840	2,915	2,920
14 Reserves excluding Revaluation Reserve						533,034
15 Earnings per share of Re.1/- each (not annualised)						
(a) Basic	7.97	5.82	6.76	20.75	20.23	26.00
(a) Diluted	7.97	5.82	6.76	20.74	20.21	25.98

NOTES:

- The above standalone unaudited financial results as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on February 9, 2016. A Limited Review of the above standalone financial results has been carried out by the Statutory Auditors.
- The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- Sales of standalone for the current quarter and nine months ended December 31, 2015 include exports Rs.197,345 lakhs and Rs.553,514 lakhs respectively (Quarter and nine months ended December 31, 2014 Rs.167,536 lakhs and Rs.489,161 lakhs respectively).
- Foreign exchange (gain)/loss for stand alone includes exchange difference of Rs.2,064 lakhs, Rs.7,396 lakhs, Rs.4,635 lakhs, for three months ended December 31, 2015, September 30, 2015, and December 31, 2014 respectively and Rs.15,884 lakhs, Rs. 12,341 lakhs for the nine months ended December, 2015 and December, 2014 respectively and Rs.7,556 lakhs for the year ended March 31, 2015 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
- The Company on July 22, 2015, had allotted 291,982,275 equity shares of Re.1/- each to the shareholders of the Company as Bonus shares in the ratio of 1:1. Consequent to the aforesaid allotment, the paid up equity share capital of the Company had increased from 291,982,275 Equity Shares of Re.1/- each to 583,964,550 Equity Shares of Re.1/- each. The earnings per share has been adjusted for bonus issue for previous periods presented in accordance with Accounting Standard 20, Earning per share.
- On 19th January, 2016 the Company has made allotment of 855,000 equity shares of Re.1/- each to the employees under Employee Stock Option Plan 2006. Consequent to the allotment the paid up share capital of the Company has increased to 584,819,550 equity shares of Re.1/- each
- During the quarter APL Holdings (Jersey) Limited, a subsidiary and APL IP Company Limited, a stepdown subsidiary of the Company have been liquidated. Actavis Deutschland GmbH & Co Kg, a step down subsidiary of the Company was renamed as Puren Pharma GmbH & Co KG.
- The Board has approved third interim dividend @70% i.e. Rs.0.70 per equity share of Rs.1/- for the year 2015-16. This is in addition to InterIm dividend @ 50% and 60% on equity share capital of Company i.e. Rs. 0.50 and Rs. 0.60 per share paid in September, 2015 and November, 2015 respectively for the year 2015-16.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.


Place: Hyderabad
Date: February 9, 2016



www.aurobindo.com

By Order of the Board

N. Govindarajan
Managing Director



AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2015

Particulars	Consolidated					
	Three months ended			Nine months ended		Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from operations						
(a) Net sales/income from operations (Net of excise duty)	343,208	328,011	314,246	997,591	889,926	1,204,323
(b) Other operating income	6,342	5,336	2,370	17,342	5,919	7,729
Total income from operations (net)	349,550	333,347	316,616	1,014,933	895,845	1,212,052
2 Expenses						
(a) Cost of material consumed	123,897	115,506	113,129	359,248	309,046	412,281
(b) Purchase of stock-in-trade	37,748	33,823	45,213	103,919	137,570	171,227
(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	(6,290)	(2,427)	(9,675)	(10,127)	(33,417)	(32,948)
(d) Employee benefits expense	40,102	37,592	33,471	114,202	92,894	130,226
(e) Depreciation and amortisation expense	9,947	9,277	6,726	28,135	24,794	33,261
(f) Other expenses	71,792	71,294	73,261	215,366	198,999	274,904
Total expenses	277,196	265,065	262,125	810,743	729,886	988,951
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	72,354	68,282	54,491	204,190	165,959	223,101
4 Other income	687	1,166	3,592	4,764	7,402	8,076
5 Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)	73,041	69,448	58,083	208,954	173,361	231,177
6 Finance costs (refer note 4)	2,270	2,407	2,189	6,762	6,171	8,431
7 Foreign exchange (Gain)/Loss (refer note 4)	(1,293)	5,790	2,020	7,055	6,080	5,960
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	72,064	61,251	53,874	195,137	161,110	216,786
9 Exceptional item	-	-	-	-	-	-
10 Profit / (Loss) from ordinary activities before tax (8-9)	72,064	61,251	53,874	195,137	161,110	216,786
11 Tax expense/(credit)	18,599	16,220	15,634	53,472	44,320	59,660
12 Net Profit / (Loss) for the period (10-11)	53,465	45,031	38,240	141,665	116,790	157,126
13 Minority Interest	(30)	(145)	(195)	(250)	(406)	(451)
14 Net Profit/(Loss) after taxes and minority interest (12-13)	53,495	45,176	38,435	141,915	117,196	157,577
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	5,840	5,840	2,915	5,840	2,915	2,920
16 Reserves excluding Revaluation Reserve						
17 Earnings per share of Re.1/- each (not annualised)						
(a) Basic	9.16	7.74	6.60	24.30	20.11	27.03
(a) Diluted	9.16	7.73	6.58	24.29	20.08	27.00

NOTES:

- The above consolidated unaudited financial results as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on February 9, 2016.
- The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and a Joint Venture.
- The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- Foreign exchange (gain)/loss for stand alone includes exchange difference of Rs.2,064 lakhs, Rs.7,396 lakhs, Rs.4,635 lakhs, for three months ended December 31, 2015, September 30, 2015, and December 31, 2014 respectively and Rs.15,884 lakhs, Rs. 12,341 lakhs for the nine months ended December, 2015 and December, 2014 respectively and Rs.7,556 lakhs for the year ended March 31, 2015 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
- During the previous year, on December 4, 2014, Company's USA subsidiary Aurobindo Pharma USA Inc. has acquired Natrol LLC, USA. The above Consolidated results for the quarter and nine months ended December 31, 2015 and for the year ended March 31, 2015 includes financial results of operations of Natrol LLC, USA from December 4, 2014. The corresponding figures of the quarter and nine months ended December 31, 2014 are not comparable.
- The Company on July 22, 2015, had allotted 291,982,275 equity shares of Re.1/- each to the shareholders of the Company as Bonus shares in the ratio of 1:1. Consequent to the aforesaid allotment, the paid up equity share capital of the Company had increased from 291,982,275 Equity Shares of Re.1/- each to 583,964,550 Equity Shares of Re.1/- each. The earnings per share has been adjusted for bonus issue for previous periods presented in accordance with Accounting Standard 20, Earning per share.
- During the quarter APL Holdings (Jersey) Limited, a subsidiary of the Company and APL IP Company Limited, a stepdown subsidiary of the Company have been liquidated. Actavis Deutschland GmbH & Co Kg, a step down subsidiary of the Company was renamed as Puren Pharma GmbH & Co KG.
- On 19th January, 2016 the Company has made allotment of 855,000 equity shares of Re.1/- each to the employees under Employee Stock Option Plan 2006. Consequent to the allotment the paid up share capital of the Company has increased to 584,819,550 equity shares of Re.1/- each
- The Board has approved third interim dividend @70% i.e. Rs.0.70 per equity share of Rs.1/- for the year 2015-16. This is in addition to interim dividend @ 50% and 60% on equity share capital of Company i.e. Rs. 0.50 and Rs. 0.60 per share paid in September, 2015 and November, 2015 respectively for the year 2015-16.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N.Govindarajan
Managing Director

Place: Hyderabad
Date :February 9 , 2016

www.aurobindo.com



Limited Review Report

**Review Report to
The Board of Directors
Aurobindo Pharma Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results of Aurobindo Pharma Limited ('the Company') for the quarter and nine months ended December 31, 2015 (the "Statement"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of standalone unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

ICAI Firm registration number: 101049W


Chartered Accountants



per Vikas Kumar Pansari

Partner

Membership No.: 093649



Place : Hyderabad

Date : February 09, 2016